REVIEW
Adoptable strategic approaches to improve outcomes of allogeneic peripheral blood stem cell transplantations from unrelated donors
Sang Kyun Sohn,
Joon Ho Moon,
Corresponding Author
Sang Kyun Sohn
Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, South Korea
Address reprint requests to: Sang Kyun Sohn, MD, PhD, Department of Hematology/Oncology, Kyungpook National University Hospital, 130 Dongdeok-Ro, Jung-Gu, Daegu 700-721, South Korea; e-mail: [email protected].Search for more papers by this authorJoon Ho Moon
Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, South Korea
Search for more papers by this authorSang Kyun Sohn,
Joon Ho Moon,
Corresponding Author
Sang Kyun Sohn
Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, South Korea
Address reprint requests to: Sang Kyun Sohn, MD, PhD, Department of Hematology/Oncology, Kyungpook National University Hospital, 130 Dongdeok-Ro, Jung-Gu, Daegu 700-721, South Korea; e-mail: [email protected].Search for more papers by this authorJoon Ho Moon
Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, South Korea
Search for more papers by this authorFirst published: 21 November 2013
This research was supported by Kyungpook National University Research Fund, 2012 (2013, 2014).
Abstract
While previous studies have shown comparable clinical results for related and unrelated bone marrow transplantation (BMT), the transplantation outcomes for related and unrelated peripheral blood stem cell transplantation (PBSCT) may not follow the same pattern due to a higher incidence of graft-versus-host disease (GVHD)-related morbidity and mortality in the case of long-term survival after unrelated PBSCT. Thus, given the higher possibility of an impaired quality of life due to severe GVHD in long-term survivors who receive unrelated PBSCT, the selection of the stem cell source needs to be decided very carefully. In addition, strategic approaches, such as the extended use of immunosuppressant as a GVHD prophylaxis, the use of antithymocyte globulins (ATGs), choosing a younger donor, and optimizing the CD34+ cell dose, need to be adopted to improve the transplantation outcomes by minimizing GVHD-related morbidity and mortality in an unrelated PBSCT setting. This review article provides a comparison of BMT and PBSCT, and related and unrelated PBSCT, plus introduces several adoptable strategies to improve the outcomes of unrelated PBSCT.
References
- 1 Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074-5087.
- 2 Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181.
- 3 Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. J Clin Oncol 2000; 18: 537-546.
- 4 Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000; 95: 3702-3709.
- 5 Friedrichs B, Tichelli A, Bacigalupo A, et al. Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol 2010; 11: 331-338.
- 6 Couban S, Simpson DR, Barnett MJ, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100: 1525-1531.
- 7 Powles R, Mehta J, Kulkarni S, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 355: 1231-1237.
- 8 Wetzko K, Blechschmidt M, Holig K, et al. Pulmonary adverse events in unrelated donors of peripheral blood stem cells. Transfus Med 2013; 23: 69-71.
- 9 Gajewski JL, LeMaistre CF, Silver SM, et al. Impending challenges in the hematopoietic stem cell transplantation physician workforce. Biol Blood Marrow Transplant 2009; 15: 1493-1501.
- 10 Delia M, Pastore D, Mestice A, et al. Outcome of allogeneic peripheral blood stem cell transplantation by donor graft CD3+/Tregs ratio: a single-center experience. Biol Blood Marrow Transplant 2013; 19: 495-499.
- 11 Ringden O, Labopin M, Beelen DW, et al. Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia: an Acute Leukaemia Working Party analysis in 2262 patients. J Intern Med 2012; 272: 472-483.
- 12 Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367: 1487-1496.
- 13 Gajewski J, Champlin R. Bone marrow transplantation from unrelated donors. Curr Opin Oncol 1996; 8: 84-88.
- 14 Chim CS, Lie AK, Liang R, et al. Long-term results of allogeneic bone marrow transplantation for 108 adult patients with acute lymphoblastic leukemia: favorable outcome with BMT at first remission and HLA-matched unrelated donor. Bone Marrow Transplant 2007; 40: 339-347.
- 15 Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 2002; 99: 1971-1977.
- 16 Passweg JR, Baldomero H, Bregni M, et al. Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transplant 2013; 48: 1161-1167.
- 17 Bittencourt H, Lopes M, de Macedo AV, et al. A retrospective comparison of allogeneic peripheral blood stem cell versus bone marrow transplantation. Hematol Oncol Stem Cell Ther 2009; 2: 272-277.
- 18 Pidala J, Anasetti C, Kharfan-Dabaja MA, et al. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1415-1421.
- 19 Ghavamzadeh A, Iravani M, Ashouri A, et al. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major. Biol Blood Marrow Transplant 2008; 14: 301-308.
- 20 Oehler VG, Radich JP, Storer B, et al. Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant 2005; 11: 85-92.
- 21 Wall DA. Allogeneic peripheral blood versus bone marrow transplantation: children are small adults and more. J Clin Oncol 2004; 22: 4865-4866.
- 22 Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002; 100: 415-419.
- 23 Cutler C, Giri S, Jeyapalan S, et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19: 3685-3691.
- 24 Nagler A, Labopin M, Shimoni A, et al. Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012; 18: 1422-1429.
- 25 Bertz H, Spyridonidis A, Ihorst G, et al. Marrow versus blood-derived stem cell grafts for allogeneic transplantation from unrelated donors in patients with active myeloid leukemia or myelodysplasia. Biol Blood Marrow Transplant 2012; 18: 894-902.
- 26 Alam N, Marras TK, Atenafu EG, et al. Allogeneic peripheral blood stem cell transplantation significantly increases risk of chronic graft-versus-host disease of lung compared with bone marrow transplantation. Biol Blood Marrow Transplant 2012; 18: 1905-1910.
- 27 Eapen M, Horowitz MM, Klein JP, et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; 22: 4872-4880.
- 28 Gonzalez A, Pardo C, Alarcon C, et al. Unrelated donor peripheral blood stem cell versus bone marrow transplantation for haematological diseases. Bone Marrow Transplant 2013; 48: S108. abstract 506.
- 29 Lee SJ, Kang BW, Moon JH, et al. Comparable analysis of outcomes for allogeneic peripheral blood stem cell transplantation from matched related and matched unrelated donors in acute myeloid leukemia. Acta Haematol 2012; 127: 81-89.
- 30 Kang BW, Moon JH, Chae YS, et al. Comparative analysis of outcomes of allogeneic peripheral blood stem cell transplantation from related and unrelated donors. Ann Hematol 2010; 89: 813-820.
- 31 Kim HJ, Kim SY, Lee MH, et al. Peripheral blood stem cell transplantation from human leukocyte antigen-matched sibling donors and unrelated donors in acute myeloid leukemia patients. Acta Haematol 2013; 130: 206-216.
- 32 Morishima Y, Kawase T, Malkki M, et al. Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013; 19: 1197-1203.
- 33 Denz U, Bertz H, Ihorst G, et al. Improved outcome in relapsed and refractory myeloid malignancies for unrelated vs related donor allogeneic peripheral blood-derived hematopoietic cell transplantation. Bone Marrow Transplant 2010; 45: 1309-1315.
- 34 Woolfrey A, Lee SJ, Gooley TA, et al. HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category. Biol Blood Marrow Transplant 2010; 16: 1382-1387.
- 35 Mengarelli A, Iori AP, Romano A, et al. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Haematologica 2003; 88: 315-323.
- 36 Gajewski J, Gjertson D, Cecka M, et al. The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant 1997; 3: 76-82.
- 37 Weisdorf D, Cooley S, Devine S, et al. T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome. Biol Blood Marrow Transplant 2012; 18: 937-943.
- 38 Bacigalupo A. Antithymocyte globulin for prevention of graft-versus-host disease. Curr Opin Hematol 2005; 12: 457-462.
- 39 Basara N, Baurmann H, Kolbe K, et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant 2005; 35: 1011-1018.
- 40 Bacigalupo A, Lamparelli T, Barisione G, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12: 560-565.
- 41 Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942-2947.
- 42 Socie G, Schmoor C, Bethge WA, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011; 117: 6375-6382.
- 43 Jacobson CA, Turki AT, McDonough SM, et al. Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 565-574.
- 44 Finke J, Schmoor C, Bethge WA, et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biol Blood Marrow Transplant 2012; 18: 1716-1726.
- 45 Ayuk F, Diyachenko G, Zabelina T, et al. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 913-919.
- 46 Moon JH, Lee YJ, Lee SJ, et al. Impact of ATG on new HLA groups for unrelated donor allogeneic stem cell transplantation. Blood 2011; 118: 3017. abstract 721.
- 47 Yu ZP, Ding JH, Wu F, et al. Quality of life of patients after allogeneic hematopoietic stem cell transplantation with antihuman thymocyte globulin. Biol Blood Marrow Transplant 2012; 18: 593-599.
- 48 Servais S, Porcher R, Xhaard A, et al. Donor characteristics as pretransplant predictive factors of long-term outcomes after allogeneic peripheral blood stem cell transplantation from HLA-matched related and unrelated donors in patients with hematologic malignancies. Blood 2012; 120: 2000. abstract 2000.
- 49 Ayuk F, Zabelina T, Wortmann F, et al. Donor choice according to age for allo-SCT for AML in complete remission. Bone Marrow Transplant 2013; 48: 1028-1032.
- 50 Sohn SK, Kim JG, Kim DH, et al. Impact of transplanted CD34+ cell dose in allogeneic unmanipulated peripheral blood stem cell transplantation. Bone Marrow Transplant 2003; 31: 967-972.
- 51 Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465-1470.
- 52 Remberger M, Ringden O, Uhlin M, et al. Impact of cell dose in BM and PBSC on outcome after allo-HSCT. Bone Marrow Transplant 2013; 48: S108. abstract 505.
- 53 Sohn SK, Jung JT, Kim DH, et al. Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies. Cancer 2002; 94: 18-24.
